🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#ESMO24 KEYNOTE-811: pembrolizumab + trastuzumab and chemotherapy for HER2+ metastatic G/GEJ adenocarcinoma: Final overall survival mFU: 50.2 mo mOS➡️20.0 vs 16.8 mo PD-L1 CPS ≥1➡️20.1 vs 15.7 mo Presented by Sara Lonardi

Another Low Dose IO trial from India 🇮🇳 CMC Vellore 🙂👍 Necesity is mother of all inventions. Our patients can not afford full dose IO so we have to modify the dose and it works 🙂👍

This is great news! Looking forward to seeing the data. Potential important impact for our EGFR mutant patients.

Oligometastatic NSCLC. How to define it ( Oligorecurrent , Oligopersistant , oligoresidual or oligoprogressive ) and some clinical evidence to approach it . Oligometastatic NSCLC needs MDT and Some of these pts do very well. ESMO - Eur. Oncology Yakup Ergün M. Bolton Brendon Stiles

‘Incurable lung cancer could be defeated with breakthrough NHS treatment’ Delighted that the TOURIST trial has been picked up by the national press! I might have phrased the headline differently… ⁦The Christie NHS⁩ ⁦Southampton CTU⁩ telegraph.co.uk/news/2024/09/2…

All questions answered by Shankar Siva at #ASTRO24 about SBRT for primary RCC

Stephen Fry describes Elon Musk perfectly here

Case report Annals of Oncology of pt with NUT carcinoma responding to lurbinectedin. Had transient response to 1L carboplatin, paclitaxel, pembrolizumab and started 2L lurbinectedin with rapid clinical and radiographic response (though only 4m). annalsofoncology.org/article/S0923-…

Why great leaders think like a farmer:

Dr Stephanie Saw discusses Asian subset data from osimertinib reminding us that osi has not performed as well in Asian subsets as non-Asian subsets, highlighting that perhaps germline EGFR intron 1 polymorphism may contribute to sensitivity #ESMOAsia24 ESMO - Eur. Oncology

NEW NICE APPROVAL published today. NICE has appraised pembrolizumab, within its marketing authorisation, as an option for the adjuvant treatment of non-small-cell lung cancer (NSCLC) with a high risk of recurrence after complete resection and platinum-based chemotherapy in

Out today in JTO & JTO CRR our case report detailing discordant IO response in biphasic diffuse pleural mesothelioma with identification of BRAF V600E and durable response to BRAF/MEK TKI. Highlights importance of NGS in this rare malignancy. jtocrr.org/article/S2666-…

👉 The first Diary of an Oncology Leader video is out. In this episode, Solange Peters shares insights on the loneliness of leadership, career challenges, and how she overcame them. Watch now for inspiration! 📹 ow.ly/yP8M50VeCz1 #W4O #GenderEquity #OncologyLeadership

Great to see our team will be walking in The Banham Marsden March 2025 for The Royal Marsden Cancer Charity! Please sponsor them, I have! Every donation helps. Thanks for your support! The Royal Marsden Cancer Charity #MarsdenMarch #TheRoyalMarsdenCancerCharity march.royalmarsden.org/st/1850/t

Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A - Journal of Thoracic Oncology jto.org/article/S1556-…

#ASCO25 A very informative poster focusing on ami+chemo efficacy outcomes in MARIPOSA2 based on plasma-detected mechanisms of resistance to osi , by great Raffaele Califano . Efficacy of the combo independent of MET amplif as a MoR or presence of TP53 mut #LCSM #some ASCO

🧬 #ASCO25 | OptiTROP-Lung03 Sacituzumab Tirumotecan (sac-TMT) vs docetaxel in EGFRm NSCLC post-TKI 🔹 Primary endpoint (ORR): 45.1% vs 15.6% (p=0.0004) 🔹 PFS: 6.9 vs 2.8 mo (HR 0.30; p<0.0001) 🔹 OS: Not reached, but strong trend (HR 0.49; p=0.007) 🔹 Crossover: 36.4% to

🔄 #ASCO25 REVIEW🔁 ☑️Tough Choices: Front-Line Treatment Dilemmas in EGFR Metastatic Non–Small Cell Lung Cancer 🔥Osimertinib Alone as Front-Line Therapy 🎙️ Julia Rotow MD OncoAlert ASCO EGFR Resisters meetings.asco.org/2025-asco-annu…

Breaking News! Score one for the good guys. US Supreme Court rules against administration attempt to defund Lung Cancer Screening, universally accepted as life-saving by identifying lung cancer at an early stage, when most curable. ASCO IASLC

🚨 #Lungcancer survival has more than doubled. New real-world data from France shows 3-year survival for lung adenocarcinoma rose from 16.3% (2000) to 38.6% (2020) driven by earlier diagnosis & targeted treatment. This is what progress looks like. But it must reach everyone who